gias, malaise, abdominal discomfort as well as leucopenia, thrombocytopenia, atypical lymphocytosis, and hepatitis are the usual clinical manifestations of symptomatic CMV infection.4 CMV pneumonitis is more common among lung transplant recipients5 6; this may in part reflect the higher levels of immunosuppression these patients receive.7 The diagnosis is made by a combination of clinical findings, serological investigations, and detection of early antigen fluorescent foci (deaff test) in blood, saliva, and urine. If there is evidence of pneumonitis, fibreoptic bronchoscopy is performed to obtain bronchoalveolar lavage for deaff testing and transbronchial lung biopsy specimens for histopathological examination. Treatment consists of intravenous ganciclovir (10 mg/kg/day), which may be supplemented by hyperimmune globulin to CMV if necessary.
Routine prophylactic treatment with either co-trimoxazole (960 mg twice daily every third day) or pentamidine isethionate by nebuliser (600 mg fortnightly) has significantly reduced the incidence of Pneumocystis carinii pneumonia. However, the organism should always be considered in the differential diagnosis of opportunistic lung infection. The presenting features may be non-specific and though the chest radiograph may show interstitial infiltration, it is often normal. This may be at variance with the clinical presentation of severe respiratory failure and arterial hypoxaemia. Fibreoptic bronchoscopy with analysis of bronchoalveolar lavage fluid and transbronchial lung biopsy specimens (using Grocott's silver methenamine preparation) to identify the organisms confirms the diagnosis. Treatment consists of oral co-trimoxazole (1 -92 g four times a day) or if patients are allergic to this, intravenous pentamidine isethionate. Alternatively, combination treatment with primaquine and clindamycin may be used.
Transplant recipients may experience reactivation of latent Toxoplasma gondii infection or may acquire primary infection from seropositive donor organs.8 An incidence of 2% for toxoplasma recrudescence and 2x4% for primary infection in heart and heart and lung transplant recipients has been reported. Clinical manifestations are mainly neurological, though myocarditis (fig 1) , pneumonitis, or disseminated lesions can also occur. Diagnosis rests on serological tests for anti- bodies to Toxoplasma gondii and the histopathological identification of the organism in biopsy material (fig 1) . Treatment consists of a 6 week course of pyrimethamine (0'5 mg/kg/day) and sulphadiazine (50-100 mg/kg/day) with folinic acid (15 mg No one single investigation is reliable. Therefore the diagnosis is reached by a combination of clinical features, serological investigations (EBV titres, clonal antibody activation to EBV), chest x ray, computed tomography scan of the affected area (fig 2) , and biopsy of lesions. Because of the wide variety of histopathological appearances, ranging from changes consistent with viral lymphadenitis to variants of high-grade nonHodgkin's lymphoma, accurate diagnosis depends on identifying EBV in the biopsy material either by immunohistochemical staining or by in situ hybridisation. Unlike conventional lymphomas, the lesions may be monoclonal or polyclonal for immunoglobulin light chain expression. Classification is based on the degree of cellular pleomorphism and clonality.9 12 Initial treatment is conservative, irrespective of the histopathological appearances and clonality, and consists of a reduction in immunosuppression and treatment with high dose acyclovir for B cell disorders. The CSA level is maintained in the region of 80-100 ng/ml (whole blood monoclonal antibody assay). T cell disorders usually respond to reduction in immunosuppression alone. 6 concentrations of 100-150 ng/ml after the first postoperative year. Long-term treatment can lead to chronic nephropathy with reduced glomerular filtration and renal plasma flow together with tubulointerstitial injury and focal glomerular sclerosis.'3 Hypertension occurs in up to 50% of patients treated with CSA for one year and usually responds to captopril or nifedipine. Other side effects include hyperkalaemia, hepatotoxicity, gingival hyperplasia, hirsutism, convulsions, and anaemia.'415 Except for anaemia, these often improve when the dose of CSA is reduced. Convulsions, which are more common in patients on intravenous therapy, are usually secondary to metabolic derangements (for example, high CSA concentration with or without hypomagnesaemia); however, intracranial pathology should be excluded. Longterm anticonvulsant treatment is not normally required. 6 The anaemia resembles that associated with chronic disease, though dysplasia in all cell lines is common (particularly in patients who are also taking azathioprine). Erythropoietin may be of benefit to those with haemoglobin concentrations <10 g/dl (provided serum iron, vitamin B,,, and folate are normal) and may obviate the need for repeated blood transfusions. If drugs known to interfere with CSA (table) are prescribed the dose of CSA must be adjusted appropriately and blood concentrations frequently monitored. In this way the risks of toxicity or of rejection caused by subtherapeutic concentrations can be avoided.
